logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jeroen J. W. M. Janssen

Radboud University Medical Center
H指数:41
被引数:6,390

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results

Asciminib单药治疗BCR::ABL1 T315I突变慢性期慢性粒细胞白血病：1期试验最终结果

Leukemia
IF13.4
2026-07-160
OAAI
Jorge E. Cortes; Delphine Rea; Michael J. Mauro; Andreas Hochhaus; Dong-Wook Kim; Koji Sasaki; Fabian Lang; Michael C. Heinrich; Massimo Breccia; Michael Deininger; Yeow-Tee Goh; Jeroen J. W. M. Janssen; Moshe Talpaz; Valle Gómez García de Soria; Philipp le Coutre; Francois-Xavier Mahon; Daniel J. DeAngelo; Andrea Damon; Shruti Kapoor; Gessami Sanchez-Olle; Matthias Hoch; Nithya Agrawal; Sara Quenet; Timothy P. Hughes
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较，包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
Fausto Castagnetti; Massimo Breccia; Elisabetta Abruzzese; Renato Bassan; Gianni Binotto; Massimiliano Bonifacio; Giovanni Caocci; Isabella Capodanno; Francesco Cavazzini; Giuseppe Cimino; Paola Fazi; Antonella Gozzini; Alessandra Iurlo; Jeroen J. W. M. Janssen; Monia Lunghi; Roberto Marasca; Bruno Martino; Monica Messina; Francesco Muriano; Francesca Paoloni; Alfonso Piciocchi; Gianantonio Rosti; Antonella Russo Rossi; Giuseppe Saglio; Simona Sica; Simona Soverini; Agostino Tafuri; Daniele Vallisa; Peter E. Westerweel; Fabrizio Pane
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中的计算性微小残留病评估：一项在HOVON-SAKK-132试验中的回顾性验证

Leukemia
IF13.4
2025-09-030
OAAI
Tim R. Mocking; Lukas H. Haaksma; Tom Reuvekamp; Angèle Kelder; Willemijn J. Scholten; Lok Lam Ngai; Dimitri A. Breems; Thomas Fischer; Bjørn T. Gjertsen; Laimonas Griškevičius; Gunnar Juliusson; Johan A. Maertens; Markus G. Manz; Thomas Pabst; Jakob R. Passweg; Kimmo Porkka; Peter J. M. Valk; Patrycja Gradowska; Bob Löwenberg; David C. de Leeuw; Jeroen J. W. M. Janssen; Gert J. Ossenkoppele; Arjan A. van de Loosdrecht; Jacqueline Cloos; Costa Bachas
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Jane F. Apperley; Dragana Milojkovic; Nicholas C. P. Cross; Henrik Hjorth-Hansen; Andreas Hochhaus; Hagop Kantarjian; Jeffrey H. Lipton; Hemant Malhotra; Dietger Niederwieser; Jerald Radich; Philippe Rousselot; Susanne Saussele; Charles A. Schiffer; Richard Silver; Simona Soverini; Leif Stenke; Anna Turkina; Luis Felipe Casado; Fausto Castagnetti; Francisco Cervantes; Richard E. Clark; Jorge Cortes; Michael Deininger; Timothy P. Hughes; Jeroen Janssen; Qian Jiang; Dong-Wook Kim; Richard A. Larson; Francois X. Mahon; Michael Mauro; Jiri Mayer; Franck E. Nicolini; Fabrizio Pane; Delphine Rea; Johan Richter; Gianantonio Rosti; Giuseppe Saglio; Rüdiger Hehlmann
ASXLI Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

ASXLI突变在诊断时并未影响慢性期（CP）慢性粒细胞白血病（CML）患者（pts）在SUSTRENIM临床试验中接受尼洛替尼（NIL）一线治疗或伊马替尼（IM）联合早期切换至尼洛替尼（NIL）（在无最佳应答情况下）的分子应答深度（MR）及无治疗缓解（TFR）资格。

BLOOD
IF23.1
2024-11-051
PRE
Soverini, Simona; De Santis, Sara; Monaldi, Cecilia; Mancini, Manuela; Giai, Valentina; Cerrano, Marco; Capodanno, Isabella; Bonifacio, Massimiliano; Abruzzese, Elisabetta; Iurlo, Alessandra; Castagnetti, Fausto; Sancetta, Rosaria; Levato, Luciano; Fava, Carmen; Tiribelli, Mario; Cavazzini, Francesco; Miggiano, Maria Cristina; Bolli, Niccolo; Tafuri, Agostino; Lucchesi, Alessandro; Vallisa, Daniele; Lunghi, Monia; Musolino, Caterina; Bruno, Samantha; Mosca, Cristina; Ciriello, Mauro; Marsili, Giovanni; Piciocchi, Alfonso; Fazi, Paola; Cavo, Michele; Janssen, Jeroen J. W. M.; Westerweel, Peter E.; Pane, Fabrizio
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study

首次完全缓解的老年急性髓性白血病患者的造血细胞移植: 一项随机III期研究的结果

HAEMATOLOGICA
IF7.9
2024-08-081
OAAI
Niederwieser, Dietger; Hasenclever, Dirk; Berdel, Wolfgang E.; Biemond, Bart J.; Al-Ali, Haifa; Chalandon, Yves; van Gelder, Michel; Junghanss, Christian; Gahrton, Goesta; Haenel, Mathias; Hehlmann, Ruediger; Heinicke, Thomas; Hochhaus, Andreas; Iacobelli, Simona; Kooy, Rien van Marwijk; Kroeger, Nicolaus; Janssen, Jeroen; Jentzsch, Madlen; Breywisch, Frank; Mohty, Mohamad; Masouridi-Levrat, Stavroula; Ossenkoppele, Gert; Passweg, Jacob; Poenisch, Wolfram; Schetelig, Johannes; Schliemann, Christoph; Schwind, Sebastian; Stelljes, Matthias; Verdonck, Leo F.; Vucinic, Vladan; Lowenberg, Bob; Cornelissen, Jan
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
LEUKEMIA
IF13.4
2024-07-102
PRE
Efficace, Fabio; Mahon, Francois-Xavier; Richter, Johan; Piciocchi, Alfonso; Cipriani, Marta; Nicolini, Franck E.; Mayer, Jiri; Zackova, Daniela; Janssen, Jeroen J. W. M.; Panayiotidis, Panayiotis; Vestergaard, Hanne; Koskenvesa, Perttu; Almeida, Antonio; Hjorth-Hansen, Henrik; Martinez-Lopez, Joaquin; Olsson-Stromberg, Ulla; Hochhaus, Andreas; Berger, Marc G.; Etienne, Gabriel; Klamova, Hana; Faber, Edgar; Rousselot, Philippe; Pfirrmann, Markus; Saussele, Susanne
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

在酪氨酸激酶抑制剂治疗 ≥ 1个T315I突变的慢性期慢性粒细胞白血病患者中单药治疗: 2年随访结果

LEUKEMIA
IF13.4
2024-05-168
OAAI
Cortes, Jorge E.; Sasaki, Koji; Kim, Dong-Wook; Hughes, Timothy P.; Etienne, Gabriel; Mauro, Michael J.; Hochhaus, Andreas; Lang, Fabian; Heinrich, Michael C.; Breccia, Massimo; Deininger, Michael; Goh, Yeow Tee; Janssen, Jeroen J. W. M.; Talpaz, Moshe; de Soria, Valle Gomez Garcia; le Coutre, Philipp; Deangelo, Daniel J.; Damon, Andrea; Cacciatore, Silvia; Polydoros, Fotis; Agrawal, Nithya; Rea, Delphine
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial (Jan, 10.1038/s41375-024-02145-6 , 2024)

更正: 用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果 (1月，10.1038/s41375-024-02145-6，2024)

LEUKEMIA
IF13.4
2024-02-280
OAAI
Flygt, Hjalmar; Soederlund, Stina; Richter, Johan; Saussele, Susanne; Koskenvesa, Perttu; Stenke, Leif; Mustjoki, Satu; Dimitrijevic, Andreja; Stentoft, Jesper; Majeed, Waleed; Roy, Lydia; Wolf, Dominik; Dreimane, Arta; Gjertsen, Bjorn Tore; Gedde-Dahl, Tobias; Ahlstrand, Erik; Markevaern, Berit; Hjorth-Hansen, Henrik; Janssen, Jeroen; Olsson-Stroemberg, Ulla
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
LEUKEMIA
IF13.4
2024-01-312
OAAI
van de Loosdrecht, A. A.; Cremers, E. M. P.; Alhan, C.; Duetz, C.; In 't Hout, F. E. M.; Visser-Wisselaar, H. A.; Chitu, D. A.; Verbrugge, A.; Cunha, S. M.; Ossenkoppele, G. J.; Janssen, J. J. W. M.; Klein, S. K.; Vellenga, E.; Huls, G. A.; Muus, P.; Langemeijer, S. M. C.; de Greef, G. E.; te Boekhorst, P. A. W.; Raaijmakers, M. H. G.; van Marwijk Kooy, M.; Legdeur, M. C.; Wegman, J. J.; Deenik, W.; de Weerdt, O.; van Maanen-Lamme, T. M.; Jobse, P.; van Kampen, R. J. W.; Beeker, A.; Wijermans, P. W.; Biemond, B. J.; Tanis, B. C.; van Esser, J. W. J.; Schaar, C. G.; Noordzij-Nooteboom, H. S.; Jacobs, E. M. G.; de Graaf, A. O.; Jongen-Lavrencic, M.; Stevens-Kroef, M. J. P. L.; Westers, T. M.; Jansen, J. H.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial

用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果

LEUKEMIA
IF13.4
2024-01-265
OAAI
Flygt, Hjalmar; Soederlund, Stina; Richter, Johan; Saussele, Susanne; Koskenvesa, Perttu; Stenke, Leif; Mustjoki, Satu; Dimitrijevic, Andreja; Stentoft, Jesper; Majeed, Waleed; Roy, Lydia; Wolf, Dominik; Dreimane, Arta; Gjertsen, Bjorn Tore; Gedde-Dahl, Tobias; Ahlstrand, Erik; Markevaern, Berit; Hjorth-Hansen, Henrik; Janssen, Jeroen; Olsson-Stroemberg, Ulla
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

针对TIM-3抗体的新型免疫疗法sabatolimab (MBG453) 与地西他滨或阿扎胞苷联合治疗高危或极高危骨髓增生异常综合征的Ib期研究

AMERICAN JOURNAL OF HEMATOLOGY
IF9.9
2023-11-2212
OAAI
Brunner, Andrew M.; Esteve, Jordi; Porkka, Kimmo; Knapper, Steve; Traer, Elie; Scholl, Sebastian; Garcia-Manero, Guillermo; Vey, Norbert; Wermke, Martin; Janssen, Jeroen J. W. M.; Narayan, Rupa; Fleming, Shaun; Loo, Sun; Tovar, Natalia; Kontro, Mika; Ottmann, Oliver G.; Naidu, Purushotham; Sun, Haiying; Han, May; White, Roisin; Zhang, Na; Mohammed, Anisa; Sabatos-Peyton, Catherine A.; Steensma, David P.; Rinne, Mikael L.; Borate, Uma M.; Wei, Andrew H.
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects
ANNALS OF HEMATOLOGY
IF2.4
2023-04-294
PRE
Geelen, Inge G. P.; Gullaksen, Stein-Erik; Ilander, Mette M.; Olssen-Stromberg, Ulla; Mustjoki, Satu; Richter, Johan; Blijlevens, Nicole M. A.; Smit, Willem M.; Gjertsen, Bjorn T.; Gedde-Dahl, Tobias; Markevarn, Berit; Koppes, Malika M. A.; Westerweel, Peter E.; Hjorth-Hansen, Henrik; Janssen, Jeroen J. W. M.
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

中等风险急性髓系白血病患者中可测量的残留疾病引导治疗是减少异基因移植而不影响生存的有价值的策略

HAEMATOLOGICA
IF7.9
2023-04-0612
OAAI
Tettero, Jesse M.; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A.; Fischer, Thomas; Gjertsen, Bjorn T.; Gradowska, Patrycja; Griskevicius, Laimonas; Janssen, Jeroen J. W. M.; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G.; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Valk, Peter J. M.; Loewenberg, Bob; Ossenkoppele, Gert J.; Cloos, Jacqueline

研究方向

暂未获取到该数据
G
Gert J. Ossenkoppele
H 指数:73论文数:624被引数:3.3万
P
Peter E. Westerweel
H 指数:30论文数:182被引数:4,436
J
Jacqueline Cloos
H 指数:58论文数:395被引数:1.5万
A
Andreas Hochhaus
H 指数:127论文数:1,647被引数:9.0万
J
Jan J. Cornelissen
H 指数:78论文数:612被引数:3.1万
B
Bjørn Tore Gjertsen
H 指数:60论文数:520被引数:1.3万
P
Peter J.M. Valk
H 指数:73论文数:508被引数:2.5万
H
Henrik Hjorth‐Hansen
H 指数:42论文数:160被引数:9,707
N
Nicole M. A. Blijlevens
H 指数:40论文数:251被引数:5,719
S
Sonja Zweegman
H 指数:87论文数:773被引数:3.2万